Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older.
- People who have been diagnosed with cirrhosis (scarring of the liver), confirmed through clinical assessment, blood tests, imaging, or a liver biopsy.
- People whose cirrhosis is linked to one or more of the following causes: alcohol use, hepatitis C, hepatitis B, fatty liver disease (NASH), excess iron in the body (hemochromatosis), autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, or an unknown cause.
- People who are already being monitored and cared for at one of the hospitals or centres taking part in this study.
- People who are enrolled in a social security or equivalent healthcare coverage program.
- People with a body weight greater than 45 kg (approximately 99 lbs).
- People who have been fully informed about the study and have given their verbal agreement to take part.
Who may not be able to join:
- People with a history of liver cancer (hepatocellular carcinoma).
- People with a history of any other type of primary or secondary cancer affecting the liver.
- People who have been diagnosed with any cancer or a blood disorder within the past 5 years (with no time limit applied for blood-related cancers).
- People who are currently receiving kidney dialysis treatment.
- People who are pregnant or breastfeeding.
- People who are under a legal protection arrangement (such as guardianship) or who are not in a position to give their own consent.
- People under the age of 18.
- People whose freedom is restricted by a court or government order.
- People receiving psychiatric care under legally mandated treatment orders (confirm with trial site).
- People who would not be able to follow the requirements of the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Mr. Franck Schreiner, Regional and University Hospital Center of Nancy
Phone: +33383153629
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Association Between mSEPT9 Test Switch and Hepatocellular Carcinoma (HCC) Development
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.